Cigna creates new program to pay for high-price gene therapies
The payer unveiled Embarc Benefit Protection, which it said would enable plans to pay a monthly, per-member fee to enroll, while patients would not have to pay anything out of pocket.
The payer unveiled Embarc Benefit Protection, which it said would enable plans to pay a monthly, per-member fee to enroll, while patients would not have to pay anything out of pocket.
While well-developed in cancers, precision medicine's readiness for prime time beyond oncology varies markedly from disease to disease. But reimbursement remains a significant hurdle.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company expects reimbursement decisions by national-level authorities in 2019 and 2020. The UK's NICE recommended Cancer Drugs Fund coverage for another high-priced Novartis therapy, the CAR-T Kymriah, earlier this month.
With a positive CHMP decision, the European Commission is expected to rule in two months, but equity research analysts foresee significant headwinds for the gene therapy.